Linked Life Data

9537457

Source:http://linkedlifedata.com/resource/pubmed/id/9537457

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9537457rdf:typepubmed:Citationlld:pubmed
pubmed-article:9537457lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C0369335lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:9537457lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:9537457pubmed:issue4lld:pubmed
pubmed-article:9537457pubmed:dateCreated1998-4-16lld:pubmed
pubmed-article:9537457pubmed:abstractTextAlthough several virus- and host-related predictive factors for the response to interferon alfa (IFN-alpha) have been defined in patients with chronic hepatitis C, no pretreatment parameter can definitely predict the response to antiviral treatment. Assessment of the initial response by quantification of serum hepatitis C virus RNA before and 4 weeks after initiation of therapy may be a clinically applicable and reliable parameter to predict long-term response. Therefore, the aims of the present study were to test the predictive value of a decline in HCV RNA of at least 3 log in the first 4 weeks of treatment (deltaHCV RNA) in patients treated with 3 x 10(6) units of recombinant IFN-alpha2a (rIFN-alpha2a) three times per week subcutaneously and to compare deltaHCV RNA with other established predictive factors, such as HCV genotype and pretreatment viremia. Serum HCV RNA was measured by a validated quantitative reverse transcription-polymerase chain reaction (RT-PCR). Geno/subtyping of HCV was performed by direct sequencing of the nonstructural (NS) 5B region of PCR-amplified isolates and subsequent phylogenetic analysis. Stable HCV RNA levels (deltaHCV RNA < or = 1 log) within the first 4 weeks of IFN-alpha treatment were present in 42 of 70 patients. A decline in HCV RNA levels between 1 to 3 log and more than 3 log was observed in 9 (13%) and 19 patients (27%), respectively. In 21 of 70 patients (30%), HCV RNA was not detectable at the end of 12 months' treatment. Three of 26 patients (11%) with a pretreatment viremia of < or = 10(6) copies/mL (all HCV subtype 3a) and 6 of 44 patients (14%) with a pretreatment viremia of > 10(6) copies/mL (HCV subtypes 1b, 2a, 2c, 3a [two patients], and 4) achieved a virological sustained response to interferon-alpha2a treatment. All patients with a virological sustained response had an initial deltaHCV RNA of more than 3 log. In a stepwise discriminant-function analysis, the initial deltaHCV RNA was confirmed as the strongest predictor of virological sustained response (P < .0001). In conclusion, the data of the present study suggest that IFN-alpha treatment can be terminated after 4 weeks in patients with a decrease in HCV RNA levels of less than 3 log, when apparent HCV eradication is considered the therapeutic target. The predictive value of deltaHCV RNA clearly exceeds the significance of HCV genotype and pretreatment viremia as predictors of successful IFN-alpha treatment.lld:pubmed
pubmed-article:9537457pubmed:languageenglld:pubmed
pubmed-article:9537457pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:citationSubsetIMlld:pubmed
pubmed-article:9537457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9537457pubmed:statusMEDLINElld:pubmed
pubmed-article:9537457pubmed:monthAprlld:pubmed
pubmed-article:9537457pubmed:issn0270-9139lld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:LeeJ HJHlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:HerrmannGGlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:FrankeAAlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:RoweW AWAlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:ZeuzemSSlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:PrümmerOOlld:pubmed
pubmed-article:9537457pubmed:authorpubmed-author:SANTANAZZlld:pubmed
pubmed-article:9537457pubmed:issnTypePrintlld:pubmed
pubmed-article:9537457pubmed:volume27lld:pubmed
pubmed-article:9537457pubmed:ownerNLMlld:pubmed
pubmed-article:9537457pubmed:authorsCompleteYlld:pubmed
pubmed-article:9537457pubmed:pagination1149-56lld:pubmed
pubmed-article:9537457pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:meshHeadingpubmed-meshheading:9537457-...lld:pubmed
pubmed-article:9537457pubmed:year1998lld:pubmed
pubmed-article:9537457pubmed:articleTitleQuantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.lld:pubmed
pubmed-article:9537457pubmed:affiliationMedizinische Klinik II, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany.lld:pubmed
pubmed-article:9537457pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9537457lld:pubmed